Invitation to the EBAC-accredited satellite symposium 'Early intervention and long-term success: navigating hyperkalemia in cardiorenal disease', at ESC HF 2024, Lisbon, Portugal.
For more information, please visit the ESC website.
Learning Objectives
Educational Objectives
- Evaluate the barriers to long-term hyperkalemia management with RAASi therapy for heart failure patients with comorbidities to improve patient outcomes
- Analyze case studies, considering the latest evidence on novel potassium binders, to optimize their use for hyperkalemia management in high-risk cardiorenal patients receiving RAASi therapy
- Develop evidence-based multidisciplinary strategies to identify, prevent, and manage hyperkalemia in patients with cardiorenal disease, focusing on early intervention, long-term maintenance, and patient-centered care.
Agenda
Chair: Gianluigi Savarese, MD - Stockholm, Sweden
12:30 – 12:45 Challenges of managing hyperkalemia in HF patients while maintaining RAASi therapy - Gianluigi Savarese, MD - Stockholm, Sweden
12:45 – 13:25 Interactive panel & case discussion: practical considerations implementing evidence and guidelines on novel potassium binders for achieving long term goals
- Aaron Wong, MD - Bridgend, Wales, United Kingdom
- James Burton, MD - Leicester, United Kingdom
- Clara Bonanad Lozano, MD, PhD - Valencia, Spain
13:25 – 13:30 Summarizing multidisciplinary strategies: Where do we go from here? - Gianluigi Savarese, MD - Stockholm, Sweden
CME Accreditation
This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
Funding
This symposium is supported by an unrestricted educational grant from AstraZeneca.
